OCRX vs CLSN(liver cancer stcoks) 1)OCRX: Phase 2 2)CLSN: doing phase 3 http://www.marketwatch.com/story/celsion-corporation-reports-year-end-2016-financial-results-and-provides-business-update-2017-03-16 The Company's lead program is ThermoDox(R) which is currently in Phase III development for the treatment of primary liver cancer